alexa Vitamin D And Biphosphonate In Neoadjuvant Advanced Breast Cancer
ISSN: 2572-4118

Breast Cancer: Current Research
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

4th World Congress on Breast Cancer
May 08-10, 2017 Singapore

Selma Sakhri
Medical oncology, Algeria
Posters & Accepted Abstracts: Breast Can Curr Res
DOI: 10.4172/2572-4118-C1-003
Abstract
Purpose: Vitamin D and calcium deficiency is associated with increased breast cancer risk and decreased breast cancer survival. The purpose of this study is to determine whether the addition of vitamin D and Zoledronic Acid (ZA) to Neoadjuvant Chemotherapy (NACT) gives complete histological responses. We report a prospective evaluation comparing complete pathological response between different biomolecular sub-groups. Patients & Methods: The study included 431 women with stages III locally advanced breast cancer who received neoadjuvant chemotherapy and Zoledronic acid. All patients were prescribed vitamin D3 (cholecalciferol) 400 IU and calcium carbonate 1,000 mg daily. The main objective is the complete histologic response. Secondary endpoints were the overall survival of patients targeted by the study. Results: Histologic complete response with Zoledronic acid and vit D was 40.13% .the higher in the subgroup Her2/luminal (RH±Her2+) and under Her2+ (HR-Her2+) and the lowest rate was observed in the triple negative group as classified by Sataloff, overall survival was 45.77 months for subgroups (Her2/luminal and in Her2+ group) vs. 44.11 months for triple negative group. Conclusion: Our study confirms the potential protective effects in vitamin D in neoadjuvant breast cancer.
Biography

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords